Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension
April 17, 2009
Santen Pharmaceutical of Japan announced earlier this week that it had signed a worldwide licensing agreement granting Merck exclusive rights to market tafluprost in North America (among other territories).
Tafluprost is a prostaglandin analogue for reduction of intraocular pressure in primary open angle glaucoma and ocular hypertension. Tafluprost is currently an investigational compound in the United States. If Tafluprost is approved in the United States, Santen will have the option to co-promote the product in the United States.
Read the full press release.
Comments
Jump down to form below to submit your own comments
One Response to “Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension”
yet another prostaglandin!
